Autonomix participates in Virtual Investor ‘What This Means’ segment

Autonomix (AMIX) Medical recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, CMO, discussed the Company’s recently announced 4-6 week positive follow-up data, from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.